

Lawrence C Long

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9568426/publications.pdf>

Version: 2024-02-01

80
papers

2,046
citations

279798

23
h-index

276875

41
g-index

88
all docs

88
docs citations

88
times ranked

2571
citing authors

#	ARTICLE	IF	CITATIONS
1	Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. <i>PLoS Medicine</i> , 2016, 13, e1002015.	8.4	232
2	The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. <i>PLoS ONE</i> , 2012, 7, e36966.	2.5	126
3	Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ART Patients to Nurses in South Africa: An Observational Cohort. <i>PLoS Medicine</i> , 2011, 8, e1001055.	8.4	106
4	The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. <i>Tropical Medicine and International Health</i> , 2008, 13, 1005-1015.	2.3	85
5	The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. <i>Aids</i> , 2010, 24, 915-919.	2.2	83
6	Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. <i>International Journal of Epidemiology</i> , 2013, 42, 430-439.	1.9	79
7	High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 500-506.	2.1	73
8	Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25640.	3.0	72
9	Scaling up Xpert MTB/RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa. <i>Tropical Medicine and International Health</i> , 2012, 17, 1142-1151.	2.3	54
10	Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. <i>PLoS ONE</i> , 2018, 13, e0204020.	2.5	53
11	Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. <i>PLoS ONE</i> , 2017, 12, e0186557.	2.5	52
12	Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. <i>Tropical Medicine and International Health</i> , 2016, 21, 1131-1137.	2.3	49
13	Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. <i>The Lancet Global Health</i> , 2021, 9, e628-e638.	6.3	47
14	Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 18651.	3.0	44
15	Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 109-116.	2.3	40
16	A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-Exposed Uninfected Compared With HIV-Unexposed Uninfected Infants and Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 1-8.	2.1	39
17	Community-based delivery of HIV treatment in Zambia: costs and outcomes. <i>Aids</i> , 2021, 35, 299-306.	2.2	33
18	Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. <i>PLoS ONE</i> , 2016, 11, e0161469.	2.5	32

#	ARTICLE	IF	CITATIONS
19	Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa. <i>AIDS Patient Care and STDs</i> , 2017, 31, 205-212.	2.5	32
20	Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. <i>PLoS ONE</i> , 2016, 11, e0158986.	2.5	31
21	Initiating antiretroviral therapy for HIV at a patient's first clinic visit. <i>Aids</i> , 2017, 31, 1611-1619.	2.2	27
22	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab040.	0.9	27
23	Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. <i>BMC Health Services Research</i> , 2018, 18, 973.	2.2	26
24	Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. <i>BMJ Open</i> , 2020, 10, e030228.	1.9	25
25	Attrition in HIV care following HIV diagnosis: a comparison of the pre-UTT and UTT eras in South Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25652.	3.0	24
26	Cost and outcomes of paediatric antiretroviral treatment in South Africa. <i>Aids</i> , 2013, 27, 243-250.	2.2	23
27	Men missing from the HIV care continuum in sub-Saharan Africa: a meta-analysis and meta-synthesis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25889.	3.0	23
28	Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis. <i>Global Health, Science and Practice</i> , 2021, 9, 296-307.	1.7	22
29	Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV services during antenatal care in Johannesburg, South Africa: a cohort analysis. <i>BMC Infectious Diseases</i> , 2015, 15, 46.	2.9	21
30	Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. <i>BMC Public Health</i> , 2019, 19, 973.	2.9	21
31	The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 94.	2.4	20
32	The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. <i>PLoS ONE</i> , 2016, 11, e0148546.	2.5	20
33	Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. <i>BMC Public Health</i> , 2014, 14, 296.	2.9	19
34	Acceptability and feasibility of a financial incentive intervention to improve retention in HIV care among pregnant women in Johannesburg, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 453-460.	1.2	19
35	Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa. <i>Drug Safety</i> , 2018, 41, 1343-1353.	3.2	19
36	Differentiated models of service delivery for antiretroviral treatment of HIV in sub-Saharan Africa: a rapid review protocol. <i>Systematic Reviews</i> , 2019, 8, 314.	5.3	19

#	ARTICLE	IF	CITATIONS
37	Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. <i>Journal of the International AIDS Society</i> , 2013, 16, 18794.	3.0	17
38	Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. <i>BMJ Open</i> , 2017, 7, bmjopen-2016-015620.	1.9	16
39	Treatment outcomes of HIV-positive patients on first-line antiretroviral therapy in private versus public HIV clinics in Johannesburg, South Africa. <i>Clinical Epidemiology</i> , 2016, 8, 37.	3.0	15
40	Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa. <i>AIDS and Behavior</i> , 2016, 20, 2717-2728.	2.7	15
41	Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. <i>BMC Health Services Research</i> , 2022, 22, 428.	2.2	15
42	The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. <i>Journal of the International AIDS Society</i> , 2014, 17, 19065.	3.0	14
43	Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 20987.	3.0	14
44	Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. <i>Tropical Medicine and International Health</i> , 2017, 22, 221-231.	2.3	13
45	Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. <i>Journal of the International AIDS Society</i> , 2020, 23, e25612.	3.0	13
46	Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 453.	2.4	13
47	“My future is bright I won't die with the cause of AIDS” ten-year patient ART outcomes and experiences in South Africa. <i>Journal of the International AIDS Society</i> , 2018, 21, e25184.	3.0	12
48	Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings. <i>Lancet HIV</i> , 2020, 7, e294-e300.	4.7	12
49	Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa. <i>PLoS ONE</i> , 2016, 11, e0168118.	2.5	12
50	Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. <i>PLoS ONE</i> , 2019, 14, e0217820.	2.5	11
51	Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. <i>Aids</i> , 2019, 33, 2049-2059.	2.2	11
52	Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. <i>Tropical Medicine and International Health</i> , 2017, 22, 241-251.	2.3	10
53	Primary healthcare seeking behaviour of low-income patients across the public and private health sectors in South Africa. <i>BMC Public Health</i> , 2021, 21, 1649.	2.9	10
54	Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. <i>Tropical Medicine and International Health</i> , 2014, 19, 490-498.	2.3	9

#	ARTICLE	IF	CITATIONS
55	Low prevalence of depressive symptoms among stable patients on antiretroviral therapy in Johannesburg, South Africa. PLoS ONE, 2018, 13, e0203797.	2.5	9
56	Will differentiated care for stable HIV patients reduce healthcare systems costs?. Journal of the International AIDS Society, 2020, 23, e25541.	3.0	9
57	High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS ONE, 2018, 13, e0205463.	2.5	8
58	Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2017, 12, e0181238.	2.5	7
59	Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open, 2017, 7, e013908.	1.9	6
60	Perceived barriers to the uptake of health services among first-year university students in Johannesburg, South Africa. PLoS ONE, 2021, 16, e0245427.	2.5	6
61	Voices from the front lines: A qualitative study of integration of HIV, tuberculosis, and primary healthcare services in Johannesburg, South Africa. PLoS ONE, 2020, 15, e0230849.	2.5	6
62	Effective public-private partnerships for sustainable antiretroviral therapy: outcomes of the Right to Care health services GP down-referral program. BMC Public Health, 2019, 19, 1471.	2.9	5
63	Dietary intake among paediatric HIV-positive patients initiating antiretroviral therapy in Johannesburg, South Africa. Vulnerable Children and Youth Studies, 2020, 15, 155-170.	1.1	5
64	Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. Gates Open Research, 2021, 5, 177.	1.1	5
65	Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Tropical Medicine and International Health, 2018, 23, 650-660.	2.3	4
66	Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS ONE, 2018, 13, e0201955.	2.5	4
67	Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa. BMC Public Health, 2019, 19, 1638.	2.9	4
68	Impact and cost of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. South African Medical Journal, 2013, 103, 436.	0.6	2
69	When donor funding leaves: an interrupted time-series analysis of the impact of integrating direct HIV care and treatment into public health services in a region of Johannesburg. Cost Effectiveness and Resource Allocation, 2019, 17, 24.	1.5	2
70	One Pill, Once a Day: Simplified Treatment Regimens and Retention in HIV Care. American Journal of Epidemiology, 2022, , .	3.4	2
71	Understanding the costs and the cost structure of a community-based HIV and gender-based violence (GBV) prevention program: the Woza Asibonisane Community Responses Program in South Africa. BMC Health Services Research, 2020, 20, 526.	2.2	1
72	<p>Using a Self-Administered Electronic Adherence Questionnaire to Identify Poor Adherence Amongst Adolescents and Young Adults on First-Line Antiretroviral Therapy in Johannesburg, South Africa<p>. Patient Preference and Adherence, 2020, Volume 14, 133-151.	1.8	1

#	ARTICLE	IF	CITATIONS
73	Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis. PLoS ONE, 2021, 16, e0248551.	2.5	1
74	Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa. Journal of the International AIDS Society, 2021, 24, e25707.	3.0	1
75	Multi-morbidities Associated with Tuberculosis in South Africa: A Systematic Review of the Literature. Wits Journal of Clinical Medicine, 2022, 4, 32-46.	0.0	1
76	Title is missing!. , 2020, 15, e0230849.		0
77	Title is missing!. , 2020, 15, e0230849.		0
78	Title is missing!. , 2020, 15, e0230849.		0
79	Title is missing!. , 2020, 15, e0230849.		0
80	Title is missing!. , 2020, 15, e0230849.		0